Studio per valutare JCXH-211 come monoterapia in pazienti con tumori solidi maligni
Uno studio di fase 1 in aperto per valutare la sicurezza, la tollerabilità e l'efficacia dell'iniezione intratumorale di JCXH-211 in pazienti con tumori solidi maligni
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase 1a and Phase 1b. Phase 1a has 3 stages, Single administration stage, Multiple administration stage and Visceral stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Texas
-
Houston, Texas, Stati Uniti, 77230-1407
- University of Texas M. D. Anderson Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
All of the following conditions should be met at screening:
- Male or female patients 18-75
- Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology
- Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist
- Patients with at least one non-injected measurable tumor lesion per RECIST v1.1
- Patients with lesions suitable for intratumoral injection (the lesion length is at least 10 mm and not exceeding 80 mm)
- Patients enrolled in the single and multiple administration stages of Phase 1a must agree to provide pre- and post-treatment tumor biopsy tissues
- Patients must have adequate organ and marrow functions
- Patients with treated brain metastases are eligible if meeting protocol's requirement
- Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from study entry:
- Patients who have received prior IL-12 either alone or as part of a treatment regimen
- Patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)
- Patients requiring therapeutic doses of anticoagulation
- Patients with tumors that impinge on major airways, blood vessels, or nerve bundles
- Patients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications
- Patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment
- Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment
- Patient with history of solid organ or allogenic bone marrow transplantation
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Phase 1a:Dose escalation
JCXH-211 will be delivered by intratumoral injection in 3 stages: Single administration stage A single administration of JCXH-211 administered to cutaneous or subcutaneous lesions in escalating doses. Multiple administration stage Up to 3 doses of JCXH-211 administered to a cutaneous or subcutaneous lesion in escalating doses. Assigned dose to be determined on the data from the single administration arm. Visceral administration stage JCXH-211 administered to a visceral lesion in escalating doses. Assigned dose to be determined on the data from the single and multiple administration arms. |
JCXH-211 administered once every 28 days |
|
Sperimentale: Phase 1b:Dose expansion
JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase 1a. |
JCXH-211 administered once every 28 days |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose limiting toxicity
Lasso di tempo: Day 1 to Day 29
|
Dose limiting toxicity, evaluated in the single administration stage of Phase 1a, which will be used to determine the MTD and to determine dose escalation |
Day 1 to Day 29
|
|
Incidence of adverse events (Safety and Tolerability)
Lasso di tempo: From consent to 30 days after the last dose of study drug
|
Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs) |
From consent to 30 days after the last dose of study drug
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective response rate (ORR)
Lasso di tempo: Up to 12 months
|
Objective response rate is defined as the proportion of patients that achieve a complete response (CR) or partial response (PR) during the study participation. |
Up to 12 months
|
|
Duration of response (DOR)
Lasso di tempo: Up to 12 months following first reported response
|
Duration of response is defined as the time from the first assessment of tumor as CR or PR to the first assessment as progressive disease or death from any cause. |
Up to 12 months following first reported response
|
|
Time to response (TTR)
Lasso di tempo: Up to 12 months from the start of study therapy
|
Time to response is defined as the time from Day 1 until the first documentation of objective response (CR or PR). |
Up to 12 months from the start of study therapy
|
|
Disease control rate (DCR)
Lasso di tempo: Up to 12 months
|
Disease control rate is defined as the proportion of patients with CR or PR or stable disease (SD) with the DOR ≥ 12 weeks observed from Day 1 to disease progression. |
Up to 12 months
|
|
Progression-free survival (PFS)
Lasso di tempo: Up to 12 months
|
Progression-free survival is defined as the time from Day 1 to disease progression or death from any cause, whichever occurs earlier. |
Up to 12 months
|
|
Overall survival (OS)
Lasso di tempo: Up to 24 months
|
Overall survival is defined as the time from Day 1 until death due to any cause. |
Up to 24 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2021-JCXH-211-001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .